In NSCLC cells resistant to the TKI dasatinib, the addition of FAK inhibitor PF-271 to dasatinib treatment inhibited tumor growth to a greater extent than either treatment alone, indicating the contribution of FAK to dasatinib resistance in NSCLC [44]. Here, PTK2 is linked to non-small cell lung carcinoma.